Cagrilintide

Cagrilintide is a long-acting amylin analog that mimics the action of the naturally occurring pancreatic hormone amylin, providing complementary metabolic effects to GLP-1 agonists through distinct receptor pathways.

• Cagrilintide activates amylin receptors in the area postrema and hypothalamus, reducing food intake by 20-35% through enhanced satiety signaling and slowed gastric emptying independent of GLP-1 pathways.

• Research demonstrates its ability to suppress postprandial glucagon secretion and glucose excursions while promoting weight loss of 10-15% as monotherapy, with enhanced effects when combined with GLP-1 agonists.

• Studies reveal unique effects on food preference and reward pathways, reducing cravings for high-calorie foods while preserving lean mass during weight loss through protein-sparing mechanisms.

Cagrilintide provides amylin-mediated appetite control, improved glycemic regulation, and synergistic metabolic effects, offering researchers a tool for investigating dual-pathway approaches to obesity and diabetes beyond incretin systems.

Composition: Cagrilintide (5 mg)